UNITED STATES OF AMERICA —GE HealthCare has signed a definitive agreement to purchase SOFIE Biosciences from private equity firm Trilantic North America for $945 million in cash. The transaction, expected to finalize in the first half of 2027 following regulatory approvals, will integrate the target company into the buyer's Pharmaceutical Diagnostics division. SOFIE Biosciences is a private contract development and manufacturing organization that specializes in radiopharmaceutical production, maintaining a United States footprint of 15 manufacturing sites equipped with 21 cyclotrons.
This capital allocation significantly alters the distribution logistics for Positron Emission Tomography radiotracers across the United States. Radiopharmaceuticals labeled with fluorine-18 exhibit a rapid decay half-life of 110 minutes, making localized manufacturing essential for clinical delivery. Securing an established network of regional facilities addresses supply chain vulnerabilities in the final stages of transport, ensuring health networks receive diagnostic compounds within strict operational timeframes.
The integration provides direct control over crucial manufacturing capacity at a time when precision oncology and theranostic therapies are expanding rapidly. Beyond infrastructure, the deal grants global rights to late-stage pipeline assets, including a Phase III diagnostic radiotracer aimed at pan-cancer imaging. As pharmaceutical developers bring dozens of new targeted tracers and therapeutic isotopes through clinical trials, specialized contract manufacturing infrastructure has become a key bottleneck for clinical adoption.
For medical providers and commercial drug developers, the consolidated entity offers a combined platform encompassing hardware manufacture, workflow software, and radiotracer distribution. Independent clinical centers stand to gain improved scheduling reliability for advanced diagnostic scans, while biotech partners retain access to expanded contract manufacturing facilities. The transaction reflects broader consolidation trends across the molecular imaging sector as major healthcare equipment vendors move downstream to capture recurring pharmaceutical revenue.
